| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$44.2M | ROE | −32.60% |
| Net Margin | — | ROIC | −84.39% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing product candidates that target proteins critical to immune cell maturation and function in the United States. Its lead candidate is soquelitinib (CPI-818), a selective covalent ITK inhibitor in Phase 1b/2 trials for peripheral T cell lymphoma, atopic dermatitis, and other conditions. It is also developing ciforadenant (CPI-444), an oral A2A receptor antagonist in Phase 2 for renal cell cancer, and mupadolimab (CPI-006), a humanized monoclonal antibody in Phase 1.
| Market Cap | $1.12B | Trading Days | 2599 |
| 52W High | 26.95 |
| 52W Low | 3.96 |
| % Off High | −50.61% |
| YTD | 72.86% | 1Y | 186.24% |
| 3Y | 481.22% | 5Y | 510.55% |
| 10Y | 3.26% | Since incept. (ann.) | −0.66% |
| Ann. Volatility (1Y) | 180.64% | Ann. Volatility (3Y) | 125.74% |
| Sharpe (1Y) | 1.10 | Sharpe (3Y) | 0.93 |
| Max Drawdown (1Y) | −56.43% | Max Drawdown (3Y) | −70.50% |
| Beta (3Y, vs SPY) | 2.57 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SDGR | Schrodinger, Inc. | $1.12B | — |
| WVE | Wave Life Sciences Ltd. | $1.13B | — |
| SPTX | Seaport Therapeutics, Inc. | $1.10B | — |
| SVRA | Savara Inc | $1.09B | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.16B | 20.8 |
| FBRX | Forte Biosciences, Inc. | $1.06B | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $1.06B | — |
| PCRX | Pacira BioSciences, Inc. | $1.05B | 167.6 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.04B | — |
| MNKD | MANNKIND CORP | $1.21B | 195.5 |
| AVTX | Avalo Therapeutics, Inc. | $1.03B | — |
| AVLN | Avalyn Pharma Inc. | $1.22B | — |